Hummingbird Bioscience Announces First Patient Dosed in Phase I Clinical Trial of HMBD-501 in Advanced HER3-Expressing Solid Malignancies (GlobeNewswire) - Jan 6, 2026 - "The Phase I clinical trial led by Hummingbird Bioscience is underway at multiple sites in the U.S....Initial data from the Phase I dose escalation is expected in the second half of 2026."
P1 data • Solid Tumor
|